Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This combination therapy involves the intradiscal administration of gelified ethanol (marketed as Discogel) alongside pulsed radiofrequency (PRF) for the treatment of chronic discogenic low back pain. Discogel is a sterile, viscous solution composed of ethyl alcohol, a cellulose derivative (ethylcellulose), and tungsten, which serves as a radiopaque agent for fluoroscopic guidance. Its mechanism of action involves inducing fluid migration from the periphery of the intervertebral disc to its center through hydrophilic and osmotic phenomena, which reinforces the disc structure and reduces intradiscal pressure. Pulsed radiofrequency is a minimally invasive neuromodulatory technique that applies a high-frequency electromagnetic field to the disc to alleviate pain without causing significant thermal tissue destruction. This specific combination was evaluated in a randomized, double-blind clinical trial conducted by researchers at Attikon University Hospital in Greece to assess its efficacy in patients refractory to conservative treatments.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gelified ethanol + pulsed radiofrequency.